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Effectiveness of Rituximab for the Treatment of
Rheumatoid Arthritis in Patients with Prior Exposure to
Anti-TNF: Results from the CORRONA Registry
Leslie R. Harrold, George W. Reed, Ashwini Shewade, Robert Magner, Katherine C. Saunders,
Ani John, Joel M. Kremer, and Jeffrey D. Greenberg
ABSTRACT. Objective. To characterize the real-world effectiveness of rituximab (RTX) in patients with rheumatoid
arthritis.
Methods. Clinical effectiveness at 12 months was assessed in patients who were prescribed RTX
based on the Clinical Disease Activity Index (CDAI). Change in CDAI was calculated (CDAI at 12
mos minus at initiation). Achievement of remission or low disease activity (LDA; CDAI ≤ 10) among
those with moderate/high disease activity at the time of RTX initiation was compared based on prior
anti-tumor necrosis factor agent (anti-TNF) use (1 vs ≥ 2) using logistic regression models.
Results. Patients (n = 265) were followed for 12 months with a mean change in CDAI of –8.1 (95%
CI –9.8 – –6.4). Of the 218 patients with moderate/high disease activity at baseline, patients with 1
prior anti-TNF (baseline CDAI 25.0) demonstrated a mean change in CDAI of –10.1 (95% CI 
–13.2 – –7.0); patients with ≥ 2 prior anti-TNF (baseline CDAI 30.0) demonstrated a mean change of
–10.5 (95% CI –12.9 – –8.0). The unadjusted OR for achieving LDA/remission in patients with
moderate/high disease activity at baseline exposed to ≥ 2 versus 1 prior anti-TNF was 0.40 (95% CI
0.22–0.73), which was robust to 4 different adjusted models (OR range 0.38–0.44).
Conclusion. A good clinical response was observed in all patients; however, patients previously treated
with 1 anti-TNF, who had lower baseline CDAI and a greater opportunity for clinical improvement
compared with patients previously treated with ≥ 2 anti-TNF, were more likely to achieve
LDA/remission. (First Release May 1 2015; J Rheumatol 2015;42:1090–8; doi:10.3899/jrheum.141043)
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improved understanding of the immunologic processes
associated with RA in the past decade has led to advances in
disease management, including approval of biologic therapies
that target the various autoimmune molecules involved in the
pathophysiology of RA. For patients who fail to respond to
nonbiologic disease-modifying antirheumatic drug (DMARD)
therapy or who develop an inadequate response over time,
anti-tumor necrosis factor (anti-TNF) therapies are typically
the first-choice biologic. Anti-TNF have demonstrated the
ability to reduce signs and symptoms of RA, inhibiting the
underlying radiographic progression, improving physical
function, and reducing disability1,2,3,4,5.
However, the effectiveness of anti-TNF varies among
patients, likely attributable to the differences in the activity
of pathophysiological pathways and cytokines that mediate
the RA disease process. Whether it is attributable to a primary
or secondary treatment failure, as many as 60% of patients
may have an inadequate response to anti-TNF therapy6.
Switching to another biologic therapy with an alternate
mechanism of action, such as rituximab (RTX), may be an
effective strategy in anti-TNF–refractory patients. RTX is a
chimeric murine/human monoclonal antibody that binds
specifically to the antigen CD20. In the United States, RTX
Rheumatoid arthritis (RA) is a chronic, systemic autoimmune
disease characterized by inflammation of the joints. An
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is indicated in combination with methotrexate (MTX) for the
treatment of patients with active disease who have not
responded to treatment with > 1 anti-TNF.
While RTX has been shown to be effective in randomized
controlled trials (RCT) among patients with RA who have
shown an inadequate response to anti-TNF7,8,9,10, these study
populations may not accurately reflect real-world patients
receiving RTX because of the strict inclusion and exclusion
criteria of these trials11,12. In clinical practice, many patients
initiating RTX have lower disease activity levels compared
with those enrolled in anti-TNF RCT, a factor that further
influences evaluations of effectiveness12,13,14. Most observa-
tional data examining the effectiveness of RTX in routine
clinical practice have been reported from European
registries15,16,17,18,19,20,21,22, with scant information currently
available from the United States23. There is tremendous value
in examining US cohorts of patients with RA to assess effec-
tiveness because of the differences in treatment practices and
patient characteristics. In many European countries, access
to biologic agents is restricted based on patient disease
activity and dosing limits. In contrast, medication selection
and dosing in the United States are typically based on the
rheumatologist’s assessment of treatment failure or success12,24.
Additionally, patients in the United States are heavier than
those in Europe25; thus, given the current label for a fixed
dose, US patients may receive fewer mg/kg of medication
per infusion.
Given the lack of data on outcomes with usual care in
US-based cohorts, the objective of our study was to charac-
terize the real-world use and effectiveness of RTX in a large
cohort of patients enrolled in the CORRONA (COnsortium
of Rheumatology Researchers Of North America) registry. In
particular, we sought to examine the effectiveness of RTX to
reduce disease activity and achieve low disease activity
(LDA) or remission. 
MATERIALS AND METHODS
Data source. CORRONA is an independent, prospective, observational
registry of patients with arthritis who were enrolled by participating rheuma-
tologists at both academic and private practice sites26,27 with data gathered
from both patients and their treating rheumatologists. As of March 3, 2014,
data have been collected from > 39,956 patients and > 600 participating
rheumatologists, yielding > 111,303 patient-years of followup. Approvals
for data collection and analyses for academic and private practice sites were
obtained from local and central institutional review boards, respectively.
Study population. Between February 28, 2006, and December 5, 2011,
30,274 patients with RA were enrolled in the CORRONA registry, of which
615 patients were newly prescribed with RTX after prior exposure to > 1
anti-TNF in accordance with the RTX label indication. No disease activity
or comorbidity exclusion criteria were required for patients with RA enrolled
into the consortium registry. Details on patient selection are presented in
Appendix 1.
Measures and data collection. Data from the CORRONA registry were
analyzed to assess RTX treatment outcomes in usual care settings. Data were
collected from both patients and their treating rheumatologists using
questionnaires that gathered information on disease severity and activity
(including components of the American College of Rheumatology response
criteria), comorbidities, use of medications including DMARD, and adverse
events26,27. Only reported first-time users of RTX were considered; patients
who restarted the drug were excluded. Baseline data were obtained at the
time of RTX initiation. In cases where RTX initiation occurred between
visits, the prior visit was considered the baseline. Followup assessments were
requested at 4-month intervals for the registry and completed during routine
clinical encounters.
Use of nonbiologic and biologic DMARD was recorded at the time of
the routine clinical visit. Data elements also documented at the time of the
clinical encounter that were relevant to the current analysis included the
Clinical Disease Activity Index (CDAI; 0–76.0) and the physician and
patient global assessments of disease activity (each a visual analog scale,
0–10.0 cm). Disease remission was defined as CDAI ≤ 2.8. LDA was defined
as a CDAI > 2.8 and ≤ 10. Moderate disease activity was defined as CDAI
> 10 and ≤ 22. High disease activity was defined as CDAI > 22.
Outcomes. Effectiveness of RTX was examined in patients based on change
in CDAI over 12 months. For all patients, we evaluated achievement of
remission at 12 months. For those with moderate or high disease activity at
the time of initiation, we examined achievement of LDA. Patients who
switched from RTX to another biologic were included in the analyses; we
used the last observation prior to the switch for evaluation of response.
Additionally, safety event rates in terms of all cardiovascular events, serious
infections, and malignancies were calculated over the 12-month period.
Statistical analysis. Patient clinical and demographic characteristics were
compared between RTX initiators who were eligible for the effectiveness
evaluation (n = 265) and those who were not (n = 111) using standard
parametric techniques to assess comparability. In the effectiveness cohort 
(n = 265), patients who were retreated with RTX or switched to other
biologic agents over the 12-month period were identified.
To evaluate the effectiveness of RTX, descriptive statistics were used to
characterize and compare patients overall and based on prior anti-TNF
exposure (1 vs ≥ 2 prior agents). Change in CDAI at 12 months from initi-
ation was calculated. Additionally, unadjusted OR comparing remission or
LDA response rates at 12 months of patients with moderate or high disease
activity at baseline previously treated with ≥ 2 vs 1 prior anti-TNF were
estimated using multivariable logistic regression.
Adjusted OR were estimated using 4 different approaches that adjusted
for baseline variables identified a priori based on their association with the
outcome and whether there was a significant univariate difference between
patients previously treated with ≥ 2 versus 1 prior anti-TNF. The variables
included a priori as covariates were based on a review of the literature and
clinical experience with regard to factors likely to influence response, and
included age, sex, duration of RA, CDAI, modified Health Assessment
Questionnaire (mHAQ) score, seropositivity [rheumatoid factor (RF) or
anticyclic citrullinated peptide antibody (anti-CCP) if RF was not available],
number of prior nonbiologics, RTX treatment with no concomitant DMARD,
and prednisone use. Propensity scores were derived by modeling exposure
to 1 or ≥ 2 prior anti-TNF as a function of age, duration of RA, CDAI, and
mHAQ. Model 1 used population-averaged (PA) logistic regression and
excluded patients with propensity scores above the maximum among those
with 1 prior anti-TNF or below the minimum among those with ≥ 2 prior
anti-TNF. Model 2 used multivariable logistic regression. Model 3 used PA
logistic regression after adjusting for clustering by practice site. Model 4
used PA logistic regression, excluded patients with high and low propensity
scores, and included the number of prior anti-TNF exposures (≥ 2 vs 1) and
propensity score as predictors. For the first 3 models, we adjusted for all the
a priori covariates because we used either the full population or the trimmed
population. For the fourth model, we adjusted using the propensity score
rather than a series of covariates.
The overall safety event rates in the effectiveness population were calcu-
lated based on the number of events divided by the duration of exposure in
patient-years (PY/100) over the 12-month period. Safety events that were
reported by providers were examined. Infections included in the analysis
were cellulitis, sinusitis, diverticulitis, sepsis, pneumonia, bronchitis,
Personal non-commercial use only. The Journal of Rheumatology Copyright © 2015. All rights reserved.
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gastroenteritis, meningitis, encephalitis, urinary tract infection, upper respi-
ratory tract infection, tuberculosis, joint infection, bursal infection, and all
other infections. Cardiovascular events included cardiac arrest, congestive
heart failure, myocardial infarction, coronary artery disease, unstable angina,
ventricular arrhythmia, cardiac revascularization, stroke, transient ischemic
attack, and deep vein thrombosis. Cancer events included breast cancer, lung
cancer, lymphoma, skin cancer (not specified, squamous cell, melanoma),
and other cancer diagnoses.
RESULTS
Demographic and clinical characteristics at baseline. By
December 5, 2011, there were 265 patients with prior
anti-TNF experience who were eligible for the evaluation of
medication effectiveness, and were similar in baseline
demographics, disease characteristics, and treatment history
to those with followup at 12 months (n = 111) but who did
not meet eligibility criteria (Table 1). From among the 265
patients who were eligible for the effectiveness evaluation,
44 (17%) switched to another biologic and 221 (83%)
remained with RTX. A total of 178 patients (67%) were
retreated with RTX (Appendix 2).
The majority of the 265 patients were women and white,
with a median age of 57 years (Table 2). The most common
non-RA comorbidity was hypertension, observed in about
35% of patients. In addition, there was a substantial number
of patients with a history of liver disease (9%), peptic ulcer
disease (9%), and cancer (15%). At baseline, patients had a
median disease duration of 13 years and significant disease
burden, with a median CDAI of 22.2, median swollen joint
count of 6, median tender joint count of 7, and median
mHAQ score of 0.6.
About 43% of patients had previous exposure to 1
anti-TNF, and 57% of patients had previous exposure to ≥ 2
anti-TNF. Patients previously treated with 1 anti-TNF had
better scores in every measurement of disease activity than
those previously treated with ≥ 2 anti-TNF at the time of RTX
initiation; however, only median CDAI was significantly
different (17.5 vs 24.4, p = 0.001). At the time of RTX initi-
ation, nearly 76% of patients started RTX in combination
with ≥ 1 nonbiologic DMARD, including 50% who received
concomitant MTX. Patients treated with 1 prior anti-TNF and
those treated with ≥ 2 prior anti-TNF were balanced in terms
of concomitant medications. A significantly greater
proportion of patients who had received ≥ 2 prior anti-TNF
were treated with concomitant prednisone compared with
those who had received 1 prior anti-TNF (49% vs 33%, p =
0.008).
Disease activity at baseline and 12 months. At baseline, about
18% of patients had LDA, 32% had moderate disease
activity, and 50% had high disease activity (Figure 1). At 12
months, about 11% of patients had achieved remission, 33%
had LDA, 28% had moderate disease activity, and 28% had
high disease activity. Overall, the mean CDAI at baseline was
24.2 and decreased to 16.1 at the 12-month followup
(DCDAImean –8.1, 95% CI –9.8 – –6.4). Patients with more
severe disease activity at baseline demonstrated a greater
Table 1. Baseline demographics, clinical characteristics, and treatment history of all RTX initiators. Values are n (%) or median (IQR) unless otherwise specified.
Characteristics All RTX Ineligible, n = 111 Eligible, n = 265 p
Initiations, n = 376
Demographics
Female 301 (80.1) 89 (80.2) 212 (80.0) 1.000
White 353 (93.9) 99 (89.2) 254 (95.9) 0.019
Age, yrs 57 (50–65) 59 (51–65) 58 (50–65) 0.641
Non-RA comorbidity history, yrs
0–1 279 (74.2) 85 (76.6) 194 (73.2) 0.780
2–3 88 (23.4) 24 (21.6) 64 (24.2)
≥ 4 9 (2.4) 2 (1.8) 7 (2.6)
Cancer 52 (13.8) 10 (9.0) 42 (15.8) 0.101
Prognostic biomarkers
Anti-CCP–positive, n/N (%) 61/86 (70.9) 14/22 (63.6) 47/64 (73.4) 0.421
RF-positive, n/N (%) 183/238 (76.9) 52/64 (81.3) 131/174 (75.3) 0.388
Characteristics n Med IQR n Med IQR n Med IQR p
RA clinical characteristics
ARA class 376 2 1–2 111 2 1–2 265 2 1–2 0.692
Duration of RA, yrs 374 13 6–21 111 12 5–19 263 13 7–22 0.259
Prior medication use
No. prior DMARD 376 2 1–3 111 2 1–3 265 2 1–3 0.299
No. prior biologics 376 2 1–3 111 2 1–3 265 2 1–3 0.073
No. prior anti-TNF 376 2 1–2 111 1 1–2 265 2 1–2 0.147
No. prior non-anti-TNF 
biologics 376 0 0–1 111 0 0–1 265 0 0–1 0.110
RTX: rituximab; IQR: interquartile range; RA: rheumatoid arthritis; anti-CCP: anticyclic citrullinated peptide antibodies; RF: rheumatoid factor; ARA: American
Rheumatism Association; DMARD: disease-modifying antirheumatic drug; anti-TNF: anti-tumor necrosis factor.
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response to RTX treatment compared with those with less
severe disease activity. Specifically, patients with LDA at
baseline demonstrated a mean increase in CDAI of 2.3 (95%
CI –0.12–4.71), whereas patients with moderate and high
disease activity at baseline demonstrated mean decreases in
CDAI of –2.2 (95% CI –4.47–0.16) and –15.5 (95% CI 
–12.2 – –8.4), respectively. When the overall sample was
stratified by previous exposure to anti-TNF, patients treated
with 1 prior anti-TNF demonstrated a mean CDAI of 20.7 at
baseline and 13.2 at 12 months; patients with ≥ 2 prior
anti-TNF demonstrated a mean CDAI of 26.8 at baseline and
18.3 at 12 months.
Concomitant use of prednisone. Among patients who started
RTX with concomitant prednisone, 31% of patients
increased, 43% of patients decreased, and 26% had no change
in their prednisone dose at 12 months. There was no signifi-
cant difference in the change in prednisone dose from
baseline between patients with previous exposure to 1
anti-TNF and those with previous exposure to ≥ 2 anti-TNF.
Treatment responses in patients with moderate or high
disease activity at baseline. About 82% of patients had
moderate or high disease activity at baseline. Of those
patients, 8% achieved remission and 29% achieved LDA at
12 months. The mean change in CDAI at the 12-month
Table 2. Baseline demographics, clinical characteristics, and treatment history of patients with a visit between
initiation and 12-month followup. Values are n (%) or median (IQR) unless otherwise specified.
Characteristics All RTX Initiations, 1 Prior Anti-TNF, ≥ 2 Prior Anti-TNF, p
n = 265 n = 113 n = 152
Demographics
Age, yrs 57 (50–65) 61 (52–69) 56 (49–63) 0.003
Female 212 (80.0) 91 (80.5) 121 (79.6) 0.878
White 254 (95.9) 106 (93.8) 148 (97.4) 0.213
History of non-RA comorbidities
CV disease 34 (12.8) 15 (13.3) 19 (12.5) 0.855
Hypertension 94 (35.5) 39 (34.5) 55 (36.2) 0.797
Diabetes 27 (10.2) 10 (8.9) 17 (11.2) 0.682
Liver disease 25 (9.4) 10 (8.9) 15 (9.9) 0.834
Peptic ulcer disease 25 (9.4) 10 (8.9) 15 (9.9) 0.834
Lung disease 25 (9.4) 10 (8.9) 15 (9.9) 0.834
All cancer 40 (15.1) 17 (15.0) 23 (15.1) 1.000
Skin cancer 10 (3.8) 4 (3.5) 6 (4.0) 1.000
Non-skin cancer 30 (11.3) 13 (11.5) 17 (11.2) 1.000
Hospitalized for infection in 
last 12 mos 4 (1.5) 2 (1.8) 2 (1.3) 1.000
RA clinical characteristics
RA duration, yrs 13 (7–22)* 10 (6–23)† 14 (8–21) 0.326
TJC 7 (2–12) 5 (1–10) 8 (3–14) 0.006
SJC 6 (2–10) 5 (1–8) 6 (2–11.5) 0.008
Patient pain 53 (29–75) 46 (20–72) 60 (31–76) 0.020
Patient global 50 (31–70) 45 (27–65) 55 (39–75) 0.005
Physician global 37 (21–53) 30 (20–50) 40 (23–58) 0.031
mHAQ disability index 0.63 (0.25–1.13) 0.63 (0.25–1.00) 0.75 (0.38–1.13) 0.271
CDAI 22.2 (12.5–32.5) 17.5 (11.0–28.0) 24.4 (14.4–35.4) 0.001
RF-positive, n/N (%) 130/173 (75.1) 55/72 (76.4) 75/101 (74.3) 0.749
Anti-CCP–positive, n/N (%) 48/65 (73.8) 24/35 (68.6) 24/30 (80.0) 0.440
Concomitant medications
No concomitant medications 61 (23.0) 26 (23.0) 35 (23.0) 0.696
MTX only 126 (47.6) 58 (51.3) 68 (44.7)
Non-MTX, nonbiologic DMARD 47 (17.7) 17 (15.0) 30 (19.7)
MTX + nonbiologic DMARD 17 (6.4) 8 (7.1) 9 (5.9)
Prednisone 112 (42.3) 37 (32.7) 75 (49.3) 0.008
Prednisone dose, mg§ 0.187
< 5 19 (17.0) 9 (24.3) 10 (13.3)
5–9 45 (40.2) 16 (43.2) 29 (38.7)
≥ 10 48 (42.9) 12 (32.4) 36 (48.0)
* n = 263. † n = 111. § Percentage based on total number of patients in each group taking prednisone. IQR:
interquartile range; RTX: rituximab; anti-TNF: anti-tumor necrosis factor; RA: rheumatoid arthritis; CV: cardio-
vascular; TJC: tender joint count; SJC: swollen joint count; mHAQ: modified Health Assessment Questionnaire;
CDAI: Clinical Disease Activity Index; RF: rheumatoid factor; anti-CCP: anticyclic citrullinated peptide
antibodies; MTX: methotrexate; DMARD: disease-modifying antirheumatic drug.
Personal non-commercial use only. The Journal of Rheumatology Copyright © 2015. All rights reserved.
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followup in patients with moderate or high disease activity
was –10.3 (95% CI –12.2 – –8.4). When stratified by
previous exposure to anti-TNF, 10% and 40% of patients with
moderate to high disease activity with previous exposure to
1 anti-TNF achieved remission and LDA at 12 months,
respectively (Figure 2). In contrast, 7% and 22% of patients
with moderate to high disease activity with previous exposure
to ≥ 2 anti-TNF achieved remission and LDA at 12 months,
respectively. The mean change in CDAI was similar between
patients previously treated with 1 anti-TNF and those previ-
ously treated with ≥ 2 anti-TNF. Patients previously treated
with 1 prior anti-TNF demonstrated a mean CDAI of 25.0 at
baseline and 14.9 at 12 months (DCDAImean –10.1, 95% CI
–13.2 – –7.0), whereas patients with ≥ 2 prior anti-TNF
Figure 1. Disease activity at baseline and 12 months (n = 265).
Figure 2. Disease activity at 12 months in patients with moderate/high disease activity at baseline (n = 218) categorized
by prior anti-TNF experience. CDAI: Clinical Disease Activity Index; anti-TNF: anti-tumor necrosis factor.
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demonstrated a mean CDAI of 30.0 at baseline and 19.5 at
12 months (DCDAImean –10.5, 95% CI –12.9 – –8.0).
Likelihood of remission or LDA in patients with moderate or
high disease activity based on prior anti-TNF exposure.
Patients with moderate or high disease activity at baseline
who were previously treated with 1 anti-TNF were signifi-
cantly more likely to achieve remission or LDA at 12 months
compared with those previously treated with ≥ 2 anti-TNF
(unadjusted OR 0.40, 95% CI 0.22–0.73). Neither presence
of autoantibodies nor cotreatment with a nonbiologic
DMARD was associated with improved efficacy in the
unadjusted analysis. The adjusted OR for achieving remission
or LDA at 12 months in patients with moderate to high
disease activity based on prior anti-TNF exposure was further
explored using 4 different logistic regression models,
including a patient-specific approach, a PA approach, and
propensity score–matching approaches (Figure 3). In all 4
models, patients treated with ≥ 2 prior anti-TNF consistently
demonstrated a significantly lower likelihood of achieving
remission or LDA compared with patients treated with 1 prior
anti-TNF (OR range 0.38–0.44). The addition of seroposi-
tivity to the models (RF or anti-CCP if RF was not available)
had no effect on the estimates in any of the models.
Safety outcomes. The incidence rate of any cancer was 1.5
events per 100 patient-years (95% CI 0.6–4.0), while skin,
lung, and breast cancer occurred at a rate of 1.1 (95% CI
0.4–3.5), 0.0 (95% CI 0.0–1.9), and 0.5 (95% CI 0.1–3.7)
events per 100 person-years, respectively. Ninety-eight
infection events were reported, resulting in an overall
incidence rate of 36.4 events per 100 person-years (95% CI
29.8–44.3). Respiratory infections were the most common
type observed (59.2%), followed by urinary tract infections
(12.2%) and cellulitis (8.2%). Three serious infection
events occurred, resulting in a rate of 1.6 events per 100
person-years (95% CI 0.5–4.9). Cardiovascular events were
infrequent, with 5 events at an incidence of 1.9 events per
100 person-years (95% CI 0.6–4.0).
DISCUSSION
In this US-based observational study of patients with
longstanding RA cared for by rheumatologists in the usual
care setting, RTX appeared effective for the treatment of
patients with prior exposure to anti-TNF. Patients treated with
≥ 2 prior anti-TNF had longer duration of disease and signifi-
cantly higher disease activity and were more frequently
treated with concomitant prednisone compared with those
with 1 prior anti-TNF. Despite these differences, improve-
ment in disease activity based on mean change in CDAI at
12 months was similar regardless of the number of prior
anti-TNF. When limiting the population to patients with
moderate or high disease activity at baseline, those treated
with 1 prior anti-TNF consistently demonstrated higher odds
of remission or LDA at 12 months compared with patients
who received ≥ 2 prior anti-TNF. This outcome was robust
to 4 logistic regression models, including 1 that adjusted for
unique differences in drug prescribing and administration by
site. These findings are likely related to the lower mean
baseline CDAI scores, and thus greater opportunity to
achieve LDA or remission among patients treated with 1 prior
anti-TNF compared with those treated with ≥ 2 prior
anti-TNF.
At baseline, most patients had moderate or high disease
activity and comorbidities not typically observed in RCT,
including a history of liver disease, peptic ulcer disease, and
Figure 3. OR (≥ 2 prior anti-TNF vs 1 prior anti-TNF) of achieving remission or LDA at 12 months in
patients with moderate/high disease activity at baseline by 4 logistic regression models. * Logistic regression
averaged over the population, excluding outliers for propensity scores. † Logistic regression. ‡ Logistic
regression averaged over the population after accounting for differences by practice site. § Logistic regression
averaged over the population, excluding outliers and adjusting for prior TNF use (≥ 2 vs 1) and propensity
scores matched for quintiles. anti-TNF: anti-tumor necrosis factor; LDA: low disease activity.
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cancer4,7,10. The demographics and RA clinical character-
istics of patients treated with RTX in our study were largely
similar to US observational cohorts of patients with RA
switching to their second or third anti-TNF24, with the
exception of worse patient global, patient pain, and physician
global assessments. Perhaps, as expected, a larger proportion
of patients in our study had moderate or high disease activity
(82%) compared with the cohort treated with anti-TNF
(56–61%)24. This suggests that physicians are preferentially
prescribing RTX over anti-TNF to the more active and severe
RA cases.
The results of our study are supported by a previously
published pooled analysis of data from 10 European registries
(Collaborating European REgistries for Rituximab in RA;
CERRERA), in which patients starting RTX who were
treated with 1 prior anti-TNF demonstrated substantial
improvement in disease activity as measured by the 28-joint
Disease Activity Score at 6 months. In fact, the response was
greater than that seen in patients treated with ≥ 2 prior
anti-TNF. In multivariate analyses, failure to respond to 1
previous biologic agent was a significantly better predictor
of the European League Against Rheumatism good response
at 3 and 6 months compared with failure to respond to 2 or
more biologic agents (OR 1.89, 95% CI 1.02–3.51)15. This
is similar to what we found regarding a decreased likelihood
of achieving remission or LDA. While mean change in CDAI
following RTX was similar in patients with 1 versus ≥ 2 prior
anti-TNF, the higher levels of disease activity in those with
exposure to ≥ 2 prior anti-TNF resulted in a lower likelihood
of achieving remission or LDA.
The optimal sequence of biologic treatment in patients
with an inadequate response to anti-TNF continues to be the
subject of much debate. Data from registries have suggested
that the response rates of patients switching to a second or
third anti-TNF are often lower than those of patients treated
with their first anti-TNF28,29. Meanwhile, a paradigm shift in
treatment strategies has occurred, with a greater focus on
“tight control”, or achievement of a predefined level of LDA
or remission within a reasonable period of time30,31. Taking
these points into consideration, the results from the current
study add to the growing body of evidence seen with other
biologics that earlier initiation of RTX may lead to tighter
control of disease activity and improved clinical outcomes in
patients with an inadequate response to an anti-TNF32. A
comparative analysis directly comparing RTX to other inter-
ventions after failure of previous anti-TNF treatment is
necessary to validate these conclusions; such a study is
currently being conducted and its results are forthcoming33.
There are strengths and limitations to this analysis. Our
study is derived from a national cohort of “real-world”
patients with detailed clinical information and is one of the
first reports of RTX effectiveness in a US patient population.
However, the care received by patients reflects current clinical
practice in the United States and is merely observational in
nature. For example, there was no mandate to retreat with
RTX at 4 to 6 months, thus the estimates of effectiveness here
may be underestimated. Patients who were treated with ≥ 2
anti-TNF had a longer disease duration and significantly
worse disease activity. They may be less likely to respond to
any drug, regardless of its mechanism of action. Additionally,
we were unable to assess radiological outcomes, neither were
we able to investigate any potential decreases in immuno-
globulin levels, a concern with RTX retreatment, in this
short-term study. The all-comers design included all RTX
initiations regardless of the reason for discontinuation of the
previous biologic — a factor that may influence effectiveness.
Lastly, these patients were identified from a registry and not
a population-based sample; thus, it is unknown how represen-
tative they are of the typical RTX-treated patient with RA.
In our study, patients with RA receiving RTX had active
and severe RA and a substantial burden of comorbid condi-
tions. Based on the mean change in CDAI, patients with
exposure to 1 and ≥ 2 prior anti-TNF demonstrated good
clinical response when treated with RTX. However, patients
exposed to 1 prior anti-TNF, who had lower CDAI at baseline
and a greater opportunity for clinical improvement, achieved
LDA or remission more frequently compared with those
exposed to ≥ 2 prior anti-TNF. This suggests that, consistent
with data from studies of other biologics, earlier intervention
with RTX in anti-TNF–experienced patients may be preferable.
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APPENDIX 1. Rituximab (RTX) initiators with 12-month followup and prior anti-TNF experience. For the purposes of our study,
we excluded RTX initiations for the following reasons: (1) unclear date of RTX infusion (n = 19), (2) no followup visits (n = 109),
and (3) did not have a followup visit 12 months following RTX infusion (n = 111). This resulted in 376 RTX initiators with > 1 year
of followup. From this cohort, we identified a subset of patients (n = 265) who met the criteria for evaluation of response and adverse
events. Specifically, from the 376 patients, we excluded those with no visit between RTX initiation and the 12-month followup visit
(n = 38), no assessment of disease activity using the CDAI at RTX initiation or at the 12-month followup visit (n = 65), and initiation
of RTX when in CDAI remission, which is seen when patients switch biologics for reasons such as cost or because of side effects to
the prior agent (n = 8). * CDAI score must have been measured within 6 months of initiation or after 2 months postinitiation. TNF:
tumor necrosis factor; CDAI: Clinical Disease Activity Index.
APPENDIX 2. Summary of rituximab (RTX) dosing and retreatment.
Within CORRONA (COnsortium of Rheumatology Researchers Of North
America), > 95% of all patients receiving RTX received the 2 × 1000 mg
dose. Among those patients who received 1 prior anti-tumor necrosis factor
(anti-TNF), 44 patients had 1 retreatment, 24 patients had 2 retreatments,
and 6 patients had 3 retreatments. The mean (SD) time to retreatment for
patients who received 1 prior anti-TNF was 7.1 (2.1) months. For those
patients who received ≥ 2 prior anti-TNF, 50 patients had 1 retreatment, 45
patients had 2 retreatments, and 9 patients had 3 retreatments. The mean
(SD) time to retreatment for patients who received ≥ 2 prior anti-TNF was
6.8 (1.8) months.
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